SG11201600067YA - Methods for controlling fucosylation levels in proteins - Google Patents

Methods for controlling fucosylation levels in proteins

Info

Publication number
SG11201600067YA
SG11201600067YA SG11201600067YA SG11201600067YA SG11201600067YA SG 11201600067Y A SG11201600067Y A SG 11201600067YA SG 11201600067Y A SG11201600067Y A SG 11201600067YA SG 11201600067Y A SG11201600067Y A SG 11201600067YA SG 11201600067Y A SG11201600067Y A SG 11201600067YA
Authority
SG
Singapore
Prior art keywords
proteins
methods
fucosylation levels
controlling
controlling fucosylation
Prior art date
Application number
SG11201600067YA
Other languages
English (en)
Inventor
Pradip Nair
Ramakrishnan Melarkode
Rasika Venkataraman
Laxmi Adhikary
Ankur Bhatnagar
Sunaina Prabhu
Kriti Shukla
Dinesh Baskar
Saravanan Desan
Harish Venkatraman Pai
Casimiro Jose Enrique Montero
Original Assignee
Biocon Ltd
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro Inmunologia Molecular filed Critical Biocon Ltd
Publication of SG11201600067YA publication Critical patent/SG11201600067YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
SG11201600067YA 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins SG11201600067YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3262CH2013 2013-07-23
IN3265CH2013 2013-07-23
PCT/IB2014/063348 WO2015011660A1 (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Publications (1)

Publication Number Publication Date
SG11201600067YA true SG11201600067YA (en) 2016-02-26

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600067YA SG11201600067YA (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Country Status (19)

Country Link
US (2) US9856502B2 (enExample)
EP (2) EP4282975A3 (enExample)
JP (1) JP6480926B2 (enExample)
KR (1) KR102062784B1 (enExample)
CN (1) CN105392878A (enExample)
AU (1) AU2014294618B2 (enExample)
BR (1) BR112016001461A2 (enExample)
CA (1) CA2926967C (enExample)
CU (1) CU24312B1 (enExample)
EA (1) EA201690269A1 (enExample)
HK (1) HK1220228A1 (enExample)
MX (1) MX2016001042A (enExample)
NZ (1) NZ716182A (enExample)
PE (1) PE20160218A1 (enExample)
PH (1) PH12016500158A1 (enExample)
SG (1) SG11201600067YA (enExample)
TW (1) TWI621711B (enExample)
WO (1) WO2015011660A1 (enExample)
ZA (1) ZA201601113B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
EP3541835B1 (en) * 2016-11-18 2026-05-13 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
KR102742590B1 (ko) * 2018-04-20 2024-12-16 (주)셀트리온 당단백질의 푸코실레이션을 조절하는 방법
CA3107038A1 (en) * 2018-08-10 2020-02-13 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CN113015805B (zh) 2018-11-13 2024-12-03 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
JP7469593B2 (ja) * 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
AU747898B2 (en) * 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
KR20080032065A (ko) 2005-06-03 2008-04-14 제넨테크, 인크. 푸코실화 수준이 조절된 항체의 생성 방법
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
AU2011237442A1 (en) * 2010-04-07 2012-10-18 Momenta Pharmaceuticals, Inc. High mannose glycans
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition

Also Published As

Publication number Publication date
EA201690269A1 (ru) 2016-05-31
WO2015011660A1 (en) 2015-01-29
KR20160036589A (ko) 2016-04-04
JP6480926B2 (ja) 2019-03-13
EP4282975A2 (en) 2023-11-29
HK1220228A1 (zh) 2017-04-28
CA2926967A1 (en) 2015-01-29
CA2926967C (en) 2020-12-08
AU2014294618B2 (en) 2019-06-27
EP4282975A3 (en) 2024-02-28
BR112016001461A2 (pt) 2017-08-29
JP2016525352A (ja) 2016-08-25
TWI621711B (zh) 2018-04-21
CN105392878A (zh) 2016-03-09
US20180087080A1 (en) 2018-03-29
US20160138065A1 (en) 2016-05-19
EP3024922A4 (en) 2017-03-29
NZ716182A (en) 2018-07-27
TW201512396A (zh) 2015-04-01
PH12016500158A1 (en) 2016-04-25
MX2016001042A (es) 2017-01-05
EP3024922A1 (en) 2016-06-01
US9856502B2 (en) 2018-01-02
PE20160218A1 (es) 2016-05-09
AU2014294618A1 (en) 2016-02-11
ZA201601113B (en) 2017-08-30
CU20160008A7 (es) 2016-11-29
CU24312B1 (es) 2018-02-08
KR102062784B1 (ko) 2020-01-07
US10308970B2 (en) 2019-06-04

Similar Documents

Publication Publication Date Title
ZA201601113B (en) Methods for controlling fucosylation levels in proteins
PL3030663T3 (pl) Kompozycje i sposoby kontroli leptinotarsa
EP3090674A4 (en) Dishwasher and control method therefor
SG11201602261VA (en) Method for producing polypeptide heteromultimer
EP2999337A4 (en) Methods for delivering cromolyn
SG11201506974XA (en) Methods for controlling t cell proliferation
SMT202000392T1 (it) Proteine leganti anti-lag-3
GB201309057D0 (en) Method
EP3090675A4 (en) Dishwasher and method for controlling same
EP3090672A4 (en) Dishwasher and method for controlling same
AU353428S (en) Controller
EP3090671A4 (en) Dishwasher and method for controlling same
GB201317883D0 (en) Control method
GB201309928D0 (en) Method
SG10201802023RA (en) Protein production method
GB201301857D0 (en) Method
GB201308057D0 (en) Protein
GB201300409D0 (en) Method
IL241779A (en) Method for protein production
GB201309654D0 (en) Method
GB201305714D0 (en) Method
GB201301233D0 (en) Method
GB2526997B (en) Controller
GB201301094D0 (en) Method
GB201401955D0 (en) Protein